Pharmaceutical - AstraZeneca

Filter

Current filters:

AstraZeneca

Popular Filters

126 to 150 of 314 results

Is downgrade cycle levelling off a signal to buy AstraZeneca stock?

12-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) shares have been weak, as defensive stocks retrench from…

AstraZenecaFinancialPharmaceutical

AstraZeneca gains rights to Merck ovarian cancer candidate

11-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US pharma giant Merck & Co (NYSE: MRK) this morning…

AstraZenecaLicensingMerck & CoMK-1775OncologyPharmaceutical

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

AstraZeneca's starts olaparib in Ph III for ovarian cancer

04-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has enrolled the first patient in the Phase III…

AstraZenecaMarkets & MarketingMyriad GeneticsolaparibOncologyPharmaceuticalResearch

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial

02-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

Rigel shares fall as asthma compound fails to meet primary endpoint

27-08-2013

Shares of USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) fell 10% to $3.27 in morning trading yesterday…

AstraZenecafostamatinibNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRigel Pharmaceuticals

AstraZeneca nabs Amplimmune for $500 million

27-08-2013

In a further bid to expand its ailing research portfolio, Anglo-Swedish drug major AstraZeneca (LSE:…

AmplimmuneAstraZenecaBiotechnologyMergers & AcquisitionsOncologyPharmaceutical

Nektar hedges bets on deal with AstraZeneca

12-08-2013

Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

AstraZeneca records fall in 2nd-qtr revenue but 21% rise in China sales

01-08-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reported second-quarter 2013 financial results with…

AstraZenecaBrilintaByettaEuropeFinancialOnglyzaPharmaceuticalSymbicort

Boehringer Ingelheim's Gilotrif could be leading therapy if it overcomes concerns, says GlobalData

18-07-2013

Family-owned German drug major Boehringer Ingelheim could face "significant challenges" over its first-line…

AstraZenecaBoehringer IngelheimEuropeGilotrifIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

Another senior departure at AstraZeneca

15-07-2013

In yet another senior executive departure at Anglo-Swedish drug major AstraZeneca (LSE: AZN), Simon Lowth,…

AstraZenecaManagementPharmaceutical

AstraZeneca target Omthera files for US approval of Epanova

09-07-2013

Emerging US specialty pharmaceutical company Omthera Pharmaceuticals (Nasdaq: OMTH) today (July 9) announced…

AstraZenecaCardio-vascularCrestorEpanovaOmthera PharmaceuticalsPharmaceutical

AstraZeneca in oncology partnerships with University of Cambridge, Cancer Research UK and Blackfield

09-07-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reached agreement with the University of Cambridge…

AstraZenecaBlackfieldBoehringer IngelheimJanssenMerck KGaAolaparibOncologyPharmaceuticalResearch

Largely negative views from Germany's IQWiG on AstraZeneca's Caprelsa in thyroid cancer

26-06-2013

In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalPricingRegulation

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

New Zealand to fund AstraZeneca's Brilinta for acute coronary syndromes

10-06-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, says it has reached an agreement with the local…

Asia-PacificAstraZenecaBrilintaCardio-vascularPharmaceuticalPricingRegulation

AstraZeneca to pay up to $1.15 billion to acquire Pearl Therapeutics

10-06-2013

In a further "strategic" bolt-on acquisition for Anglo-Swedish drug major AstraZeneca (LSE: AZN) in less…

AstraZenecaMergers & AcquisitionsPearl TherapeuticsPharmaceuticalPT003Respiratory and Pulmonary

126 to 150 of 314 results

Back to top